WestEnd Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$28.8K Buy
24
+2
+9% +$2.04K ﹤0.01% 69
2026
Q1
$20.2K Hold
22
﹤0.01% 68
2025
Q4
$23.6K Sell
22
-2
-8% -$1.91K ﹤0.01% 70
2025
Q3
$18.3K Sell
24
-10
-29% -$7.44K ﹤0.01% 65
2025
Q2
$26.5K Buy
34
+3
+10% +$2.33K ﹤0.01% 59
2025
Q1
$25.6K Buy
31
+21
+210% +$17.5K ﹤0.01% 61
2024
Q4
$7.72K Buy
10
+1
+11% +$828 ﹤0.01% 75
2024
Q3
$7.97K Sell
9
-1
-10% -$899 ﹤0.01% 69
2024
Q2
$9.05K Sell
10
-3
-23% -$2.4K ﹤0.01% 67
2024
Q1
$10.1K Buy
13
+1
+8% +$712 ﹤0.01% 65
2023
Q4
$7K Buy
12
+1
+9% +$584 ﹤0.01% 69
2023
Q3
$5.91K Buy
+11
New +$5.67K ﹤0.01% 70
2023
Q1
Sell
-9
Closed -$3.04K 72
2022
Q4
$3.29K Sell
9
-1
-10% -$355 ﹤0.01% 69
2022
Q3
$3K Hold
10
﹤0.01% 76
2022
Q2
$3.24K Buy
+10
New +$3K ﹤0.01% 77
2022
Q1
Sell
-6
Closed -$1.54K 77
2021
Q4
$1.66K Buy
+6
New +$1.52K ﹤0.01% 89
2021
Q3
Hold
0
88
2021
Q2
Hold
0
86

Other funds holding LLY

WestEnd Advisors's LLY Position: Q2 2026 in Review

WestEnd Advisors increased its Eli Lilly (LLY) stake by 9.1% in Q2 2026, buying an estimated $2.04K and bringing the position to 24 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #69.

WestEnd Advisors first reported a position in LLY in Q4 2021 and has held it in 16 quarters since. 4,614 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • WestEnd Advisors held 24 shares of Eli Lilly worth $28.8K as of Q2 2026.
  • WestEnd Advisors bought 2 Eli Lilly shares in Q2 2026, an estimated $2.04K.
  • Eli Lilly made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #69 holding.
  • WestEnd Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 16 quarters since.
  • 4,614 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.